Momenta Pharmaceuticals Announces Presentation of Data Supporting Sialylation Platform

CAMBRIDGE, Mass., May 2, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will present its approach to designing novel therapeutics by applying site-specific sialylation to Fc glycans in IVIg, monoclonal antibodies, and other recombinant Fc-containing proteins, in a presentation entitled "Embracing Complexity: Understanding IVIg to Rationally Engineer Novel Therapeutics". The presentation will be given by Tony Manning, Ph.D., Vice President of Research at Momenta, at 12:10 pm on Monday, May 5, 2014 at the PEGS annual meeting in Boston.

Momenta has thoroughly characterized a wide range of IVIg preparations to understand the detailed composition of this plasma-derived product. Using molecular, cellular, and animal models of disease, supplemented by an analysis of samples from human patients treated with IVIg, the company has developed a detailed understanding of the biological basis for the therapeutic effects of IVIg. Momenta scientists now have a broad and comprehensive understanding of the composition of IVIg and its mechanism of action as an anti-inflammatory therapeutic. This research has informed the company's approach to the rational design of several novel, differentiated therapeutic agents.

Momenta has also optimized the process for applying site-specific sialylation to Fc glycans in antibodies, including IVIg and monoclonal antibodies, as well as other recombinant Fc-containing proteins. In his presentation, Dr. Manning will present data that demonstrate the enhanced anti-inflammatory activity of these sialylated agents across a broad range of animal models of autoimmune disease, including inflammatory arthritis, immune thrombocytopenic purpura (ITP), pemphigus, and experimental autoimmune encephalomyelitis (EAE). Finally, Dr. Manning will discuss how this research has led to approaches for rationally engineering other novel recombinant product candidates which display potential as broad anti-inflammatory therapeutics.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel drugs.

Forward Looking Statements 

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including product development plans and expectation or the success of any product plans or candidates, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the company's Annual Report on Form 10-K for year ended December 31, 2013 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

To receive additional information about Momenta, please visit the website at, which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

CONTACT: IR Contact: Momenta Pharmaceuticals, Inc. Business Development Contact: businessdevelopment@momentapharma.comSource:Momenta Pharmaceuticals